Journal of Clinical Oncology

Papers
(The H4-Index of Journal of Clinical Oncology is 133. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.861
The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer.811
Knowledge and use of different breast cancer screening tools among primary care physicians: A cross-sectional study.640
Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population, a national inpatient sample study.583
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.580
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.556
A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.545
Integrated clinico-genomic characterization of pancreatic ductal adenocarcinoma in an Asian population.529
Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer.489
Representativeness of patients with lung cancer in an integrated health care delivery system.461
The molecular signature of gain-of-function (GOF) vs. non-GOF classification TP53 mutations in colorectal cancer.452
Reevaluating the role of adjuvant chemotherapy in early-stage, resectable NSCLC with high-risk clinical and pathologic features.422
Outcomes of renal function and efficacy in patients with muscle invasive bladder cancer treated by tislelizumab-based immunochemotherapy.417
Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases.413
Incidence of solid malignancies (SM) among patients with Waldenström macroglobulinemia (WM): Analysis of the SEER database (2000-2019).390
Attachment avoidance and anxiety impacting dyadic coping and communication in patients with metastatic sarcoma and their family caregivers.390
Early integration of exercise into breast cancer care: The MSK healthy living program.389
Comparison of diversity across real-world evidence, randomized clinical trial, and Surveillance, Epidemiology, and End Results (SEER) data in patients with metastatic breast cancer.386
Impact of economic inequality on Kaposi sarcoma of the lung: A retrospective cohort.373
Information and decisional needs of patients (pts) with newly diagnosed advanced cancer in the hospital: A multi-level, mixed-methods study.349
Cascade genetic testing (CGT) female first-degree relatives (FDR) of men with germline BRCA2 mutations (gBRCA2mut) and prostate cancer (PCa): A cost-effectiveness analysis.346
Efficacy and safety of penpulimab-containing regimens for advanced malignant solid tumors that have failed immunotherapy: A real-world study.338
Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07.336
Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital.335
Leadership knowledge and beliefs regarding diversity, equity, and inclusion at SWOG Cancer Research Network.327
Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).326
Multi-omics study of the genomic features and clinical characteristics of hepatic sarcomatoid carcinoma located at different sites.304
Clinical validation of next-generation sequencing-based clonality assays for minimal residual disease tracking in multiple myeloma.303
Body image disturbances in adolescent and young adult patients with cancer confronting infertility risk and fertility preservation decisions.298
Is Medicare Advantage associated with more favorable health care access, acute care utilization, and affordability among beneficiaries with cancer?296
Sun exposure and associated risks: Insight from an international survey with a focus on the organ transplant recipient population.296
Enhancing patient clinical streamlining (EPACS) pilot in the breast medicine service at memorial sloan kettering cancer center.292
Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and trastuzumab alone or in combination with pertuzumab in human epidermal growth factor receptor-2 breast cancer patie289
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NS283
Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controll282
Arterial chemotherapy in advanced hepatocellular carcinoma: An evolutionary trajectory exploration and pooled outcome analysis.277
Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.275
Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.274
Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: A prospective study.272
The impact of using Elsevier ClinicalPath oncology treatment pathways on survival and cost of care.272
Impact of neighborhood deprivation on disability free survival in patients with aggressive B cell non-Hodgkin lymphoma.271
Predicting therapy-induced cardiomyopathy in long-term survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).266
A national survey of current scenario and future perspectives of cancer research in Brazil.263
The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study.259
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.258
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.257
Impact of SARS-COV2 infection on the clinical outcomes in patients with lung cancer compared to all other cancers.254
The efficacy and safety of anlotinib combined with bevacizumab in treatment of recurrent isocitrate dehydrogenase wildtype glioblastoma: A retrospective analysis.253
Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05).249
Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis.248
Tracking MRD and neoantigen targets using a tumor-informed liquid biopsy platform in HCC patients treated with personalized cancer vaccine and pembrolizumab.246
Ten-year outcomes of hypofractionated (45 Gy in 9 fractions) intensity-modulated radiotherapy for localized prostate cancer.245
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.243
A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuva235
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx stud234
3D genomics identifies previously unreported yet clinically actionable gene fusions and complex rearrangements in a cohort of driver-negative colorectal carcinoma tumors.234
Positive margin and advanced depth of invasion as the indicators for assessing the necessity of adjuvant chemoradiotherapy in early-stage oral cavity squamous cell carcinoma.232
Clinicopathologic features and outcomes associated with induction regimen intensity among older veterans with myeloma.228
Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.217
ERBB2 (HER2) gene amplification concordance analysis of circulating tumor cells and tumor tissue in patients with breast cancer.217
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.216
A study on oligo-progression after durvalumab plus platinum-etoposide for ES-SCLC.209
Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.208
Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).205
Concurrent EGFR wild-type tongue squamous cell carcinoma and EGFR-mutant lung adenocarcinoma and response to osimertinib.203
Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.200
Clinical and molecular Characterization of NSCLCs with MET exon 14 skipping mutation coexist MET amplification.200
Racial and income characteristics and the burden of illness among metastatic prostate cancer patients.194
Tp53 as a potential therapeutic biomarker in patients with recurrent high-grade glioma treated with anlotinib and temozolomide.193
Efficacy and safety of pembrolizumab plus chemotherapy and sequential surgical resection in initial unresectable stage IIIB NSCLC.187
A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors.187
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing granulocytopenia in sarcoma patients receiving doxorubicin combined with ifosfamide: A prospective, randomized, non-inferiority phase II186
Healthcare utilization among individuals diagnosed with hereditary breast-ovarian cancer syndrome through a universal germline genetic testing program.186
Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.186
The Ohio State University Guardant Shield Colorectal Cancer Screening Project.185
Correlation of patient characteristics and tumor histology in patients (pts) with locally advanced cutaneous squamous cell carcinoma (LACSCC) receiving immune checkpoint inhibitor treatment (ICI): A r184
Donafenib combined with anti-PD-1 antibody as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective analysis.184
Artificial neural network model analysis in T790M detection after failure of first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.184
Association of patient and tumor characteristics with outcomes in young patients with head and neck squamous cell carcinoma (HNSCC).184
The impact of COVID-19 on anxiety among breast cancer survivors before, during and after the pandemic.183
Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.182
Patterns of diversity in cancer clinical trial enrollment at a New York City academic health system, 2018-2022.182
A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).180
UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.180
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.180
FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.180
Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival.175
Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy.172
Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina.170
Understanding the late immune checkpoint inhibitor (ICI) symptom experience using an electronic patient reported outcomes (ePRO) app-based platform: The immunowave study.170
Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.169
Therapeutic interchange: The cornerstone of cost effectiveness in the Oncology Care Model performance for the U.S. Oncology Network.168
Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.168
A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.167
Development of a remote monitoring program for melanoma/skin oncology patients at Princess Margaret Cancer Centre.166
Beyond gemtuzumab ozogamicin: A systematic review of antibody therapies for acute myeloid leukemia.166
The impact of virtual live education on the competence and knowledge of gynecologists caring for ovarian cancer patients.165
Scenery of multilocus inherited neoplasia alleles syndrome (MINAS) in a single Brazilian institution.165
A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.164
Mutational profiles of sporadic synchronous colorectal cancer.161
Clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma.161
A real-world study of prognostic factors and risk-stratification model from Taiwanese patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regi160
Pan-Cancer analysis of the mutation frequency of genes in DDR pathway in Chinese population.157
Evaluation of serum vascular endothelial growth factor as a biomarker in Erdheim-Chester disease.156
A cross sectional study on female sexual function following pelvic radiotherapy.154
Improving goal concordant care clinician workshops: Do patients benefit?153
Filling the gap in competency-based training for medical oncology with supervised online patient counseling: A qualitative study.152
Hereditary cancer screening at an urban safety net hospital.152
Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer.151
Associations between genomic instability score (GIS), molecular characterization, and clinical outcomes in high grade serous ovarian cancers (HGSOC).151
Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.148
Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials.148
Participation in cancer research in BNSSG, England: A Health Equity Audit 2021.148
Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC).147
Genomic characterization of papillary thyroid carcinoma in Chinese Shandong population.146
The relationship of oncotype Dx Recurrence Score (RS) with Ki 67 in early stage breast cancer patients in a community based cancer center in rural central Nebraska.146
Is recent FDA guidance on HRQoL clinical significance a barrier to clinician/patient treatment risk/benefit discussions: An example using EORTC scale endpoints in a randomized, phase 3 trial.145
Race- and sex-based variation in industry research and general payments to medical oncologists in the United States.144
CD47 expression patterns in thymic epithelial tumors.144
Non-invasive cell-free DNA monitoring for predicting the response to neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma.144
Characterization of patients with metastatic melanoma that relapses following complete metabolic response from anti–PD-1 therapy.143
Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.141
Financial distress, health literacy, numeracy, and treatment receipt by race/ethnicity amongst breast cancer survivors.141
Genomic landscape and clonal evolution between adenocarcinoma and squamous components in adenosquamous carcinoma of the pancreas.139
Are we providing adequate information? patient-specific clinical trial information at NCI-designated cancer center websites.138
Systematic assessment of online health information related to drug therapy for non-small cell lung cancer.138
Awareness of the link between HPV, cervical cancer, and HPV vaccination: An online survey among Polish women.137
Multi-modal single-cell profiling of sarcomas from archival tissue reveals mechanisms of resistance to immune checkpoint inhibitors.137
Variation in survival rates among patients with angiosarcoma based on demographic and socioeconomic factors in academic versus non-academic settings: An NCDB analysis.137
Randomized controlled trial (RCT) of symptom screening with targeted early palliative care (STEP) versus usual care in patients with advanced cancer.136
Polymorphism rs4673 and plasma paraoxonase 1 level for prediction and early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer.136
Trends in the incidence of early-onset invasive colorectal cancer between 1990 and 2018, stratified by race/ethnicity, gender, and anatomic sub-sites among Pennsylvania residents.134
Effectiveness of immunotherapy versus BRAF/MEK inhibitors in treatment-naïve BRAF-mutant advanced melanoma: A single institution retrospective analysis.134
A multicenter, case-control study of a novel multi-target fecal DNA test for colorectal cancer detection.133
Vulnerable patients with metastatic colorectal cancer in a real-world setting: A multicenter retrospective study.133
Tumour radiomics as imaging biomarker of tumour response to chemo-radiotherapy in patients with adenocarcinoma of rectum.133
Adult BMI change over time and risk of colorectal adenoma.133
0.038555860519409